Medicamen Biotech Ltd

₹ 244 -0.57%

08 Jun 10:19 a.m.

medicamen.com BSE: 531146 NSE: MEDICAMEQ

About

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations^[1]

Key Points

Business Overview:^[1]^[2]^[3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.

Website BSE NSE

Market Cap ₹ 331 Cr.
Current Price ₹ 244
High / Low ₹ 454 / 217
Stock P/E 34.3
Book Value ₹ 203
Dividend Yield 0.42 %
ROCE 5.43 %
ROE 3.95 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter

Cons

The company has delivered a poor sales growth of 11.9% over past five years.
Company has a low return on equity of 4.23% over last 3 years.
Dividend payout has been low at 14.5% of profits over last 3 years
Company has high debtors of 151 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	38.67	41.94	43.54	46.50	47.32	43.05	44.74	45.14	29.61	43.04	47.17	46.91	60.65
	32.18	34.99	38.89	41.60	41.57	39.60	39.43	38.43	31.22	38.43	42.01	42.53	55.22
Operating Profit	6.49	6.95	4.65	4.90	5.75	3.45	5.31	6.71	-1.61	4.61	5.16	4.38	5.43
OPM %	16.78%	16.57%	10.68%	10.54%	12.15%	8.01%	11.87%	14.86%	-5.44%	10.71%	10.94%	9.34%	8.95%
	0.35	0.38	0.55	0.83	0.57	0.59	0.29	0.14	5.23	0.47	0.37	0.53	1.74
Interest	0.86	0.96	0.91	0.65	1.89	0.71	1.04	0.76	0.65	1.15	0.99	0.97	0.38
Depreciation	1.62	1.69	1.82	1.80	1.77	1.77	2.61	2.21	0.48	1.80	1.86	1.83	1.73
Profit before tax	4.36	4.68	2.47	3.28	2.66	1.56	1.95	3.88	2.49	2.13	2.68	2.11	5.06
Tax %	13.53%	15.81%	39.68%	38.11%	22.93%	48.72%	53.85%	24.74%	25.30%	24.88%	21.27%	22.27%	12.06%
	3.77	3.95	1.47	2.03	2.04	0.80	0.91	2.92	1.87	1.60	2.12	1.64	4.45
EPS in Rs	3.07	3.30	1.19	1.90	1.68	1.06	1.15	2.73	1.90	1.59	1.97	1.61	2.85
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	123	125	113	115	141	179	163	198
	105	106	93	91	117	156	148	178
Operating Profit	17	20	20	24	24	24	14	20
OPM %	14%	16%	17%	21%	17%	13%	9%	10%
	4	2	1	2	2	2	6	3
Interest	1	1	2	2	3	6	4	4
Depreciation	2	2	3	6	6	7	7	7
Profit before tax	18	18	16	18	17	13	10	12
Tax %	31%	26%	26%	18%	14%	27%	34%	18%
	12	13	12	15	15	9	7	10
EPS in Rs	10.28	10.88	9.93	12.20	11.73	8.60	5.59	7.11
Dividend Payout %	10%	5%	10%	8%	9%	12%	18%	14%

Compounded Sales Growth
10 Years:	%
5 Years:	12%
3 Years:	12%
TTM:	22%

Compounded Profit Growth
10 Years:	%
5 Years:	-4%
3 Years:	-13%
TTM:	36%

Stock Price CAGR
10 Years:	11%
5 Years:	-15%
3 Years:	-28%
1 Year:	-42%

Return on Equity
10 Years:	%
5 Years:	6%
3 Years:	4%
Last Year:	4%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	12	12	12	12	13	13	13	14
Reserves	75	109	121	134	181	194	200	262
	12	11	19	26	26	31	34	48
	38	49	42	53	59	56	50	49
Total Liabilities	137	181	194	226	279	295	297	372
	24	34	90	92	93	92	87	85
CWIP	15	40	0	0	0	0	0	0
Investments	0	0	0	0	0	0	0	0
	97	107	104	133	186	203	210	287
Total Assets	137	181	194	226	279	295	297	372

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	4	13	13	4	-6	-7	-8	-33
	-15	-37	-18	-8	-6	-6	-1	-3
	-4	19	6	4	29	6	-1	64
Net Cash Flow	-14	-5	1	-0	17	-6	-11	28
Free Cash Flow	-11	-25	-5	-4	-13	-13	-10	-38
CFO/OP	48%	88%	88%	30%	-13%	-16%	-47%	-159%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	129	145	170	200	169	112	155	151
Inventory Days	67	78	27	188	228	234	268	251
Days Payable	134	173	169	302	241	154	184	144
Cash Conversion Cycle	62	51	28	86	156	193	239	259
Working Capital Days	116	130	126	147	156	123	186	193
ROCE %		16%	13%	12%	10%	8%	6%	5%

Insights

In beta

Mar 2015

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Export Sales as % of Total Turnover
% ・Standalone data

xx.xx	xx.xx			xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
	xxx,xxx	xxx,xxx	xxx,xxx	xxx,xxx	xxx,xxx	xxx,xxx		xxx,xxx
			xx	xx	xx	xx		xx
					xx	xx		xxx
				xxx		xxx		xxx
			x.xx			x.xx		xx.xx
				xxx			xxx	xxx
							xxx	xxx
								xx

Please log in to see hidden values.

Manufacturing Facilities Area
Sq. Ft. ・Standalone data

Number of Countries with Active Marketing
Number ・Standalone data

Domestic Marketing Team Size
Number

Gross Current Assets (GCA) Days
Days

R&D Spend as % of Sales
% ・Standalone data

Total Products Registered
Number ・Standalone data

Products under Registration / Filing / Development
Number ・Standalone data

Oncology SKUs
Number ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	43.21%	43.21%	43.21%	43.21%	42.99%	42.99%	42.99%	43.16%	40.46%	40.46%	40.46%	40.46%
	0.16%	0.22%	0.22%	0.12%	0.06%	0.06%	0.06%	0.12%	0.00%	0.05%	0.02%	0.10%
	0.20%	0.20%	0.67%	0.99%	1.17%	1.17%	0.87%	0.69%	0.64%	0.59%	0.44%	0.00%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.06%	0.05%	0.05%	0.05%	0.05%
	56.44%	56.38%	55.90%	55.69%	55.78%	55.79%	56.04%	55.99%	58.83%	58.84%	59.02%	59.39%
No. of Shareholders	8,272	9,419	10,252	10,639	10,652	10,792	10,576	10,435	10,808	11,177	10,967	10,806

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	45.51%	45.37%	44.53%	44.77%	44.83%	43.60%	43.21%	43.21%	43.16%	40.46%
	0.14%	0.49%	0.49%	0.47%	0.44%	0.40%	0.19%	0.12%	0.12%	0.10%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%	0.99%	0.69%	0.00%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.05%
	54.35%	54.14%	54.99%	54.76%	54.73%	56.01%	56.40%	55.69%	55.99%	59.39%
No. of Shareholders	4,095	4,802	4,684	4,542	4,965	9,300	8,233	10,639	10,435	10,806

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Nov 2024

Transcript

AI Summary
PPT
Dec 2021

Transcript

AI Summary
PPT
Nov 2020

Transcript

AI Summary
PPT
Aug 2020

Transcript

AI Summary
PPT
Jun 2020

Transcript

AI Summary
PPT